 BERKELEY, Calif., Oct. 20, 2021 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq:CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous President and Chief Executive Officer, will present a company overview at the following upcoming investor conferences. 